Improving patient retention after botulinum toxin type A treatment
- PMID: 16442041
- DOI: 10.1111/j.1524-4725.2006.32038.x
Improving patient retention after botulinum toxin type A treatment
Abstract
Background: Botulinum toxin treatments have been associated with consistently high patient satisfaction rates, but calculation of patient retention rates is not routinely performed. Retention measurements serve as critical indicators of clinical performance and can be optimized by evaluation of current office policies and implementation of strategies to improve patient retention.
Purpose: To investigate the reasons patients discontinue botulinum toxin treatments and to evaluate the effect of a single intervention intended to improve patient retention.
Methods: A retrospective chart review was performed of all patients who received botulinum toxin injections in a private cosmetic dermatology practice over a 2-year time period to determine the patient retention rate. Patients who had discontinued botulinum toxin treatment after a single session were surveyed to discern their reasons for terminating treatment. A change in office policy was instituted wherein all patients who received their first botulinum toxin treatment were required to undergo a 2-week post-treatment evaluation to determine treatment effect and to receive touch-up treatment as necessary. Retention rates were calculated over the 1-year period immediately after initiation of the new policy.
Results: The initial patient retention rate was 55%. The most common reasons cited for discontinuance of botulinum toxin treatments were procedural cost, patient failure to re-schedule, perceived lack of product longevity, and clinical effect falling short of expectations. After initiation of the mandatory 2-week post-treatment office evaluation, a 67% patient retention rate was achieved.
Conclusions: Managing patient expectations of botulinum toxin treatments and mandatory post-treatment appointments for evaluation of the initial procedure increase the patient retention rate.
Comment in
-
Letter: Benzyl alcohol preserved saline used to dilute injectables poses a risk of contact dermatitis in fragrance-sensitive patients.Dermatol Surg. 2007 Nov;33(11):1396-7. doi: 10.1111/j.1524-4725.2007.33300.x. Dermatol Surg. 2007. PMID: 17958600 No abstract available.
Similar articles
-
Botulinum toxin products overview.Skin Therapy Lett. 2008 Jul-Aug;13(6):1-4. Skin Therapy Lett. 2008. PMID: 18806905
-
A Systematic Review of Patient-Reported Outcomes for Cosmetic Indications of Botulinum Toxin Treatment.Dermatol Surg. 2019 May;45(5):668-688. doi: 10.1097/DSS.0000000000001878. Dermatol Surg. 2019. PMID: 30893170
-
Botulinum toxin injection for facial wrinkles.Am Fam Physician. 2014 Aug 1;90(3):168-75. Am Fam Physician. 2014. PMID: 25077722 Review.
-
Addressing recent concerns in comparative studies of botulinum toxin type A.J Cosmet Laser Ther. 2010 Oct;12(5):246-8. doi: 10.3109/14764172.2010.514918. J Cosmet Laser Ther. 2010. PMID: 20825255 No abstract available.
-
Oculofacial contour asymmetries: Management of combined treatment with hyalurostructure and botulinum toxin injections.J Cosmet Laser Ther. 2012 Apr;14(2):111-6. doi: 10.3109/14764172.2012.655286. Epub 2012 Feb 28. J Cosmet Laser Ther. 2012. PMID: 22373036
Cited by
-
The Treatment In Morning versus Evening (TIME) study: analysis of recruitment, follow-up and retention rates post-recruitment.Trials. 2017 Nov 23;18(1):557. doi: 10.1186/s13063-017-2318-4. Trials. 2017. PMID: 29169373 Free PMC article. Clinical Trial.
-
[Botulinum toxin treatment : therapy success in cases of depression and ongoing pension applications].Nervenarzt. 2009 Jun;80(6):712-6. doi: 10.1007/s00115-009-2690-8. Nervenarzt. 2009. PMID: 19294358 Clinical Trial. German.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical